The global C-reactive protein testing market was valued at USD 1.90 Billion in 2022 and is expected to reach USD 2.23 Billion by 2031 , expanding at a CAGR of 1.8% during the forecast period, 2023 – 2031. The growth of the market is attributed to increasing number of diseases such as rheumatoid arthritis, inflammatory bowel disease, cancer, and cardiovascular diseases.
C-reactive protein (CRP) is a substance produced by the liver, due to inflammation. C-reactive protein is known as High-Sensitivity C-reactive protein (HS-CRP) and Ultra-Sensitive C-reactive protein (US-CRP). A high level of CRP in blood causes inflammation in the body, which results in small infections to severe diseases.
C-reactive protein is measured in milligram of CRP per liter of blood (mg/L).
Reading
|
Risk
|
Less than 1 mg/L
|
Low risk of cardiovascular disease
|
Between 1 and 2.9 mg/L
|
Intermediate risk
|
Between 3 and 9.9 mg/L
|
High risk
|
High reading of above 10 mg/L indicates severe diseases including:
- Bone infection
- IBD
- Cancer
- Lupus, connective tissue disease, or other autoimmune diseases
- Tuberculosis
- Pneumonia
- Autoimmune arthritis flare-up
- Other diseases
Market Trends, Drivers, Restraints, Opportunity
-
Increasing number of diseases such as rheumatoid arthritis, inflammatory bowel disease, cancers, and cardiovascular diseases, is a major driving force for the market.
-
Technological advancement in diagnostics and increasing investments for diagnostics research are expected to drive the market during the forecast period.
-
Increasing initiatives by international bodies for the prevention and treatment of chronic disorders is significantly accelerating the growth of the C-reactive protein testing market during the forecast period.
-
Presence of bacterial and viral infection is diagnosed by C-reactive protein testing, which helps drive the market.
-
Lack of public awareness regarding CRP (C-reactive protein) testing restrains the market growth.
-
Other blood tests such as erythrocyte sedimentation rate (ESR) give accurate results when compared with the C-reactive protein testing market, which restrains the market growth.
Scope of the Report
The report on the global C-reactive protein testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title |
C Reactive Protein Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Overall Period
|
2020–2031
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast
|
Global C-reactive Protein Testing Market Segment Insights
Based on assay types, the market is divided into immunoturbidimetric, ELISA, Turbidometric, and others. The immunoturbidimetric assay segment has a considerable market share and this trend is expected to continue during the forecast period. Availability of highly sensitive automated immunoturbidimetric assays and increased exploratory activities in immunoturbidimetric assays are expected to play an important role in the field of immunoturbidimetric assays.
On the basis of applications, the market is divided into cardiovascular disease, cancer, diabetes, rheumatoid arthritis, inflammatory bowel disease, endometriosis, lupus, and others. The cardiovascular disease segment has a considerable market share and this trend is expected to continue during the forecast period. Factors such as rising incidence of cardiovascular diseases, rapid growth of the elderly population, and increasing use of CRP testing to determine the risk of heart attack or stroke are anticipated to play an important role in the field of cardiovascular diseases.
In terms of end-uses, the market is segregated into clinics, hospitals, diagnostic labs, and others. The clinics segment has a considerable market share and this trend is expected to continue during the forecast period. Testing in primary health care institutions, availability of testing, and increasing need to improve the diagnosis and treatment of chronic inflammatory diseases in primary and secondary health care institutions are expected to play an important role in the clinics segment.
Based on regions, the market is divided into North America, Asia Pacific, Latin America, Middle East and Africa, and Europe. Asia Pacific has a significant market share and this trend is expected to continue during the forecast period. The market in Asia Pacific is majorly driven by the development of advanced CRP testing, development of modern medical facilities, and lifestyle changes, which led to an increase in the prevalence of cardiovascular diseases.
Segments
Assay Types
- Immunoturbidimetric
- ELISA
- Turbidometric
- Others
Applications
- Cardiovascular disease
- Cancer
- Diabetes
- Rheumatoid Arthritis
- Inflammatory Bowel Disease
- Endometriosis
- Lupus
- Others
End-uses
- Clinics
- Hospitals
- Diagnostic Labs
- Others
Regions
- North America
- Asia-Pacific
- Middle East and Africa
- Latin America
- Europe
Key Player
- Hoffmann-La Roche Ltd.
- Danaher
- Quest Diagnostics Incorporated
- Siemens
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- Merck KGaA
- Abaxis Inc.
- Ortho Clinical Diagnostics
- Getein Biotech Inc.
- HORIBA Ltd.
- Randox Laboratories Ltd.
- BODITECH MED INC.
- Aidianm
Competitive Landscape
In the competitive environment, companies are adopting different strategies to capture the market and offer tough competition to their competitors. Companies focus on R&D, product launches, product approvals, patents, merger & acquisitions, partnerships, and collaborations. These strategies help in capturing large market share in the long-run. Some of the key players in the market are: Hoffmann-La Roche Ltd., Danaher, Quest Diagnostics Incorporated, Siemens, Abbott Laboratories, Laboratory Corporation of America Holdings, Merck KGaA, Abaxis, Inc., Ortho Clinical Diagnostics, Getein Biotech, Inc., HORIBA, Ltd., Randox Laboratories Ltd., BODITECH MED INC., and Aidianm.